BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
December 04, 2018 08:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
November 19, 2018 08:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
November 07, 2018 08:00 ET
|
BrainStorm Cell Therapeutics Inc.
Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics...
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
October 29, 2018 08:00 ET
|
BrainStorm Cell Therapeutics Inc.
Highlights Scientific Advances and Continued Progress for NurOwn® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn® in a Second...
BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
October 17, 2018 08:30 ET
|
BrainStorm Cell Therapeutics Inc.
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading...
BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
October 04, 2018 09:18 ET
|
BrainStorm Cell Therapeutics Inc.
Translational Insights Support NurOwn® as a Best-In-Class Strategy in ALS NEW YORK and PETACH TIKVAH, Israel, Oct. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a...
BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
October 03, 2018 06:10 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for...
BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®
September 13, 2018 07:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform
September 12, 2018 08:49 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating...
BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
September 05, 2018 11:36 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...